Resumen
Lung cancer is one of the leading cancers worldwide, with a poor prognosis and high mortality. Recent studies show that epigenetic mechanisms such as neddylation contribute to compromised cellular differentiation. Lung cancer cells largely exposed to conventional chemotherapy, mainly EGFR-tyrosine kinase inhibitors (TKI) (e.g., gefitinib, erlotinib, and afatinib), acquire stem-like properties that contribute to chemoresistance and tumor relapse in vitro and in vivo. Therefore, the inhibition of neddylation appears to be crucial for the understanding of the underlying reprogramming events driving tumorigenesis and an attractive epigenetics-based approach to anticancer therapies.